AU3170499A - Fibroblast growth factor mutein compositions and methods of use therefor - Google Patents

Fibroblast growth factor mutein compositions and methods of use therefor

Info

Publication number
AU3170499A
AU3170499A AU31704/99A AU3170499A AU3170499A AU 3170499 A AU3170499 A AU 3170499A AU 31704/99 A AU31704/99 A AU 31704/99A AU 3170499 A AU3170499 A AU 3170499A AU 3170499 A AU3170499 A AU 3170499A
Authority
AU
Australia
Prior art keywords
methods
growth factor
fibroblast growth
use therefor
factor mutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU31704/99A
Inventor
Ramnarayan Kalyanaraman
Hengyi Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of AU3170499A publication Critical patent/AU3170499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU31704/99A 1998-04-28 1999-04-15 Fibroblast growth factor mutein compositions and methods of use therefor Abandoned AU3170499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6792998A 1998-04-28 1998-04-28
US09067929 1998-04-28
PCT/JP1999/002013 WO1999055861A2 (en) 1998-04-28 1999-04-15 Fibroblast growth factor mutein compositions and methods of use therefor

Publications (1)

Publication Number Publication Date
AU3170499A true AU3170499A (en) 1999-11-16

Family

ID=22079349

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31704/99A Abandoned AU3170499A (en) 1998-04-28 1999-04-15 Fibroblast growth factor mutein compositions and methods of use therefor

Country Status (2)

Country Link
AU (1) AU3170499A (en)
WO (1) WO1999055861A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774958B2 (en) * 1999-10-02 2004-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Fibroblast growth factor-5 (FGF-5) is a tumor associated T-cell antigen

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4552700A (en) * 1999-04-19 2000-11-02 Ballermann, Barbara Jutta Gene therapy
JP2005507363A (en) * 2001-02-16 2005-03-17 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Angiogenesis-inhibiting tripeptides, compositions and methods of their use
JP2005052001A (en) * 2001-07-05 2005-03-03 Takara Bio Inc Gene therapeutic agent
CN1302109C (en) * 2004-04-21 2007-02-28 中国人民解放军军事医学科学院基础医学研究所 Horny cell growth factor mutant and its preparation method and use thereof
JP5767314B2 (en) 2010-04-16 2015-08-19 ソーク インスティチュート フォー バイオロジカル スタディーズ Methods for treating metabolic disorders using FGF
CN102477093B (en) * 2010-11-22 2014-03-12 中国人民解放军军事医学科学院基础医学研究所 Preparation method of thermal-stable human keratinocyte growth factor mutant and application of preparation method
US11103553B2 (en) 2013-09-25 2021-08-31 Trefoil Therapeutics, Inc. Modified fibroblast growth factors for the treatment of ocular disorders
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
WO2017127493A1 (en) * 2016-01-22 2017-07-27 Salk Institute For Biological Studies Fgf2 truncations and mutants and uses thereof
KR102440312B1 (en) * 2020-08-28 2022-09-05 한국해양과학기술원 Thermally stable fgf7 polypeptide and use of the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000198A1 (en) * 1987-07-07 1989-01-12 Biotechnology Research Associates, J.V. Recombinant fibroblast growth factors
WO1989004832A1 (en) * 1987-11-24 1989-06-01 Amgen Inc. Analogs of fibroblast growth factor
JP3039802B2 (en) * 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア Receptor for fibroblast growth factor
TW275068B (en) * 1993-09-24 1996-05-01 American Cyanamid Co
EP0730651B1 (en) * 1993-09-24 2005-07-06 Wyeth Holdings Corporation Surface loop structural analogues of fibroblast growth factors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774958B2 (en) * 1999-10-02 2004-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Fibroblast growth factor-5 (FGF-5) is a tumor associated T-cell antigen

Also Published As

Publication number Publication date
WO1999055861A3 (en) 2000-04-20
WO1999055861A2 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
AU2886399A (en) Intraluminal shunt and methods of use
AU2609901A (en) Antimicrobial compositions and methods of use
AU5520998A (en) Reduction of hair growth
AU3599597A (en) Reduction of hair growth
AU1532297A (en) Starch-emulsifier composition and methods of making
AU6298894A (en) Compositions and methods for promoting hair growth
AU9319798A (en) Reduction of hair growth
AU2655097A (en) Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents
AU5730298A (en) Reduction of hair growth
AU3494397A (en) Fibroblast growth factor receptor activating gene i and related compositions and methods
AU5282200A (en) Methods of reducing factor viii clearance and compositions therefor
AU5800399A (en) Polish composition and method of use
AU4215399A (en) Dermatological compositions and methods
AU1403501A (en) Novel composition and use
AU3170499A (en) Fibroblast growth factor mutein compositions and methods of use therefor
AU2111399A (en) Wear reducing compositions and methods for their use
AU1903799A (en) Compositions and methods for modulating the activity of fibroblast growth factor
EP1248844B8 (en) Analogs of human basic fibroblast growth factor
AU1152601A (en) Compositions and their use
AU1522400A (en) Substituted pyrimidine compositions and methods of use
AU5914299A (en) Antagonists of fibroblast growth factor
AU6412599A (en) Oxybutynin formulations and methods of use
AU1856297A (en) Lyst1 and lyst2 gene compositions and methods of use
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU1350699A (en) Compositions and methods for modulating the activity of fibroblast growth factor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase